Cinnamic Acid Prodrug Formulation for Sustained Benzoate Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders and glycine encephalopathy, such as sodium benzoate, require frequent high-dose administration due to rapid excretion, causing side effects like nausea and drowsiness, and there is a need for a sustained-release alternative.
Innovation Solution
The use of cinnamic acid as a prodrug that metabolizes to benzoate in the liver, providing a sustained release of benzoate and reducing the frequency of administration, potentially combined with glyceryl tribenzoate and glyceryl dibenzoate for slow-release formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium benzoate is administered at high doses frequently, then therapeutic effectiveness is maintained, but side effects such as nausea, vomiting, and drowsiness increase
Solution Approach 1:
Cinnamic acid serves as an intermediary prodrug that is metabolized to benzoate in the body. This intermediary approach allows the drug to be delivered in a form that converts to the active compound, enabling sustained release and reducing the need for frequent high-dose administration, thereby decreasing side effects while maintaining therapeutic effectiveness
Solution Approach 2:
The prodrug cinnamic acid is administered in advance and converted to benzoate through metabolic processes. This preliminary action allows the active compound to be released gradually over time, maintaining effective concentrations without requiring frequent dosing, thus reducing side effects while preserving therapeutic reliability
2Loss of substance
If sodium benzoate is excreted rapidly from the body, then elimination of the drug occurs, but frequent re-administration is required to maintain effective concentration
Solution Approach 1:
Cinnamic acid provides continuous release of benzoate through metabolic conversion, ensuring sustained therapeutic levels in the body. This continuous action approach counteracts rapid excretion by continuously generating the active compound, maintaining effective concentration over extended periods and reducing dosing frequency
Solution Approach 2:
The prodrug cinnamic acid acts as a reservoir that continuously converts to benzoate, serving as an intermediary system that compensates for rapid excretion. This intermediary mechanism ensures steady supply of the active compound, reducing the time loss associated with frequent re-administration
3Duration of action of moving object
If cinnamic acid is used as a prodrug, then sustained release of benzoate is achieved, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
Cinnamic acid is metabolized to benzoate through the body's natural metabolic pathways without requiring external conversion systems. This self-service approach allows sustained release to be achieved using the body's existing enzymatic machinery, minimizing the need for complex delivery systems or additional components, thus extending duration of action while limiting complexity increase
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cinnamic acid maintains a therapeutically effective dose of benzoate in the body, potentially reducing side effects and allowing for less frequent dosing, thereby effectively treating neurodegenerative disorders and glycine encephalopathy.
Implementation Method 1
After intake, these three active compounds are converted into cinnamic acid by oxidation and hydrolysis
Implementation Method 2
After intake, these three active compounds are converted into cinnamic acid by oxidation and hydrolysis
Implementation Method 3
The cinnamic acid is then β-oxidized to benzoate in the liver
Data Source
AI summary
This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of a neurodegenerative disorder or glycine encephalopathy. The pharmaceutical compositions may include cinnamic acid. The pharmaceutical compositions and formulations may be orally administered to the patient.